Author

Daniela Abriss

Observed names: Abriss Daniela, D. Abriss

Institution: Boston Children's Hospital

Observed institutions: Goethe University Frankfurt, Boston Children's Hospital, Harvard University, Johannes Gutenberg University Mainz, German Red Cross, University Hospital Frankfurt, Georg Speyer Haus, DRK-Blutspendedienst Baden-Württemberg - Hessen, Harvard Stem Cell Institute, Dana-Farber/Boston Children's Cancer and Blood Disorders Center

OpenAlex ID: A5083458681

Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease

2020 · Erica B. Esrick, Leslie E. Lehmann, et al. · New England Journal of Medicine · 446

Preclinical Evaluation of a Novel Lentiviral Vector Driving Lineage-Specific BCL11A Knockdown for Sickle Cell Gene Therapy

2020 · Christian Brendel, Olivier Negre, et al. · Molecular Therapy — Methods & Clinical Development · 72

Chemical Chaperones Improve Protein Secretion and Rescue Mutant Factor VIII in Mice with Hemophilia A

2012 · Stefanie D. Roth, Jörg Schüttrumpf, et al. · PLoS ONE · 43

Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous Disease

2018 · Christian Brendel, Michael Rothe, et al. · Human Gene Therapy Clinical Development · 36

Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells

2024 · Jing Zeng, My Anh Nguyen, et al. · Cell stem cell · 33

Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice

2011 · Peter Milanov, Lacramioara Ivanciu, et al. · Blood · 32

Oxygen‐induced changes in hemoglobin expression in Drosophila

2008 · Eva Gleixner, Daniela Abriss, et al. · FEBS Journal · 29

CD133-targeted Gene Transfer Into Long-term Repopulating Hematopoietic Stem Cells

2014 · Christian Brendel, Benjamin Goebel, et al. · Molecular Therapy · 25

Transgene Loss and Changes in the Promoter Methylation Status as Determinants for Expression Duration in Nonviral Gene Transfer for Factor IX

2010 · Jörg Schüttrumpf, Peter Milanov, et al. · Human Gene Therapy · 20

Oral gene therapy for hemophilia B using chitosan‐formulated FIX mutants

2014 · P. Quade‐Lyssy, P. Milanov, et al. · Journal of Thrombosis and Haemostasis · 19

Flipping the Switch: Initial Results of Genetic Targeting of the Fetal to Adult Globin Switch in Sickle Cell Patients

2018 · Erica B. Esrick, Christian Brendel, et al. · Blood · 16

Next generation FIX muteins with FVIII‐independent activity for alternative treatment of hemophilia A

2014 · P. Quade‐Lyssy, D. Abriss, et al. · Journal of Thrombosis and Haemostasis · 11

Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial

2022 · Erica B. Esrick, Amy Federico, et al. · Blood · 9

Factor VIII-eGFP fusion proteins with preserved functional activity for the analysis of the early secretory pathway of factor VIII

2009 · Stefan Heinz, Jörg Schüttrumpf, et al. · Thrombosis and Haemostasis · 5

Combined +58 and +55 BCL11A enhancer Editing Yields Exceptional Efficiency, Specificity and HbF Induction in Human and NHP Preclinical Models

2021 · Jing Zeng, Selami Demirci, et al. · Blood · 2

Improving Hematopoietic Stem Cell Based Gene Therapy By Targeting CD133+ Cells

2013 · Benjamin Goebel, Christian Brendel, et al. · Blood

Works count: 16

Citation count: 797

H-index: 11

I10-index: 12